Fractyl Health, Inc. (GUTS) stock
Close on Nov 11, 2026Market cap $11.69MP/E –Yield –
Fractyl Health, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$90.89M. At the latest close the market valued the company at $11.69M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $11.69M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$74.20M
- EPS, diluted
- -$6.00
- Free cash flow
- -$90.89M
- Book value per share
- -$1.00
- Diluted shares
- 13M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $0.81
- Open
- $0.82
- Day's range
- $0.80 – $0.89
- Volume
- 141,088
- Average volume (20 days)
- 1,183,451
- Beta (5 years)
- 1.67
- 52-week range
- $0.80 – $29.34
- RSI (14 days)
- 20.8
- Volatility (1 year)
- 133.3%
- Relative volume
- 0.37×
- WACC
- 7.7%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GUTS | S&P 500 | Difference | GUTS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -80.1% | -2.4% | −77.7 pts | ||
| 3 months | -89.5% | -1.2% | −88.4 pts | ||
| Year to date | -96.7% | +12.3% | −109.0 pts | ||
| 1 year | -93.3% | +12.4% | −105.8 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fractyl Health filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Results
- Update
- Update
About Fractyl Health
Surgical & Medical Instruments & Apparatus
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company's lead product candidate is Revita, an outpatient procedural medical device designed to remodel the duodenal mucosal lining via duodenal mucosal resurfacing. In addition, Fractyl is advancing its Rejuva gene therapy platform, which includes lead candidate RJVA-001, targeting metabolic pathways to provide sustained disease-modifying benefits for patients.
Company profile, executives and historyFractyl Health stock: common questions
What is Fractyl Health's stock price?
GUTS closed at $0.88 on Nov 11, 2026, up 8.70% on the day. Over the past 52 weeks it traded between $0.80 and $29.34.
What is Fractyl Health's market cap?
Fractyl Health was worth $11.69M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GUTS's P/E ratio?
Fractyl Health lost money over the twelve months to Sep 30, 2026 (diluted EPS -$6.00), so it has no meaningful P/E ratio.
How much revenue does Fractyl Health make?
Fractyl Health reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Fractyl Health pay a dividend?
No. Fractyl Health has not paid a cash dividend over the last twelve months.
When does Fractyl Health report earnings next?
Fractyl Health is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GUTS stock performed over the past year?
Including dividends, GUTS returned -93.3% over the past year, against +12.4% for the S&P 500.
How many GUTS shares are sold short?
1M shares were sold short at the latest FINRA report, 13.00% of the float, or 1.0 days of average trading volume.
Who are Fractyl Health's competitors?
Companies most similar to Fractyl Health by business, industry and size include PFSA, PAVM, RDGL, QTEX, GIPL.
See a number that looks wrong?